✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Suven Pharmaceuticals Ltd.

SUVENPHAR

Market Cap
₹30,656 Cr.
P/E
109.79

Suven Pharmaceuticals Ltd.

  • Suven Pharma
  • Jubilant Pharmova
  • Syngene Internation.
  • TJI Pharma - API & CRAMS
FAQs on Suven Pharmaceuticals Ltd. Shareprice

Suven Pharma has given better returns compared to its competitors.
Suven Pharma has grown at ~59.88% over the last 2yrs while peers have grown at a median rate of 24.65%

Yes, Suven Pharma is expensive.
Latest PE of Suven Pharma is 109, while 3 year average PE is 47.82.
Also latest EV/EBITDA of Suven Pharma is 81.66 while 3yr average is 36.34.

View FAQ's On Business
Growth Table
  • Suven Pharmaceuticals Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Balance Sheet
  • Suven Pharmaceuticals Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Suven Pharmaceuticals Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Cash Flow
  • Suven Pharmaceuticals Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Suven Pharmaceuticals Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Quarterly Results
  • Suven Pharmaceuticals Ltd.
  • Jubilant Pharmova
  • Syngene Internation.
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Suven Pharmaceuticals Ltd. Financials

Balance sheet of Suven Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Suven Pharma is increasing.
Latest debt of Suven Pharma is -₹33.08 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹62.36 Crs.

No, profit is decreasing.
The profit of Suven Pharma is ₹279 Crs for TTM, ₹300 Crs for Mar 2024 and ₹411 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Suven Pharma latest dividend payout ratio is 37.14% and 3yr average dividend payout ratio is 32.59%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech